Market Mover: Cellectar (CLRB) Climbs at Midday August 5

Equities Staff  |

Cellectar Biosciences Inc (NASDAQ: CLRB) shares climbed 12.28%, or $0.56 per share, as on 11:12:52 est today. Opening the day at $4.89, 14,290 shares of Cellectar have been traded today and the stock has moved between $5.14 and $4.92.  

So far this year the company has a YTD change of 24.70%.

Cellectar is set to release earnings on 2022-08-08.

For technical charts, analysis, and more on Cellectar visit the company profile.

About Cellectar Biosciences Inc

Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The company's product pipeline includes one preclinical PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets.

To get more information on Cellectar Biosciences Inc and to follow the company's latest updates, you can visit the company's profile page here: Cellectar Biosciences Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content